CClinicalTrials.gg
Sign In
Status unknownNCT00192829Updated Apr 11, 2007

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

An observational study in Non-Small Cell Lung Carcinoma and Venous Thromboembolism, sponsored by Rambam Health Care Campus. Status unknown at 2 sites in Israel. Per ClinicalTrials.gov, last updated 2007-04-11.

Sponsored by Rambam Health Care Campus · Observational

The sponsor has not verified this record recently (last verified Mar 2007), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Time perspective
Prospective
Enrollment
100
Sex
All
01

Study summary

The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).

02

Conditions studied

  • Non-Small Cell Lung Carcinoma
  • Venous Thromboembolism

Keywords

  • Lung cancer
  • Thrombosis
  • Hypercoagulable
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's enrollment of 100 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Rambam Health Care Campus is the lead sponsor of 456 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • normal serum bilirubin
  • informed concent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • anticoagulant therapy
  • infectious disease
05

Study design

Time perspective
Prospective
Enrollment
100 participants

Interventions

  • ProcedureBlood sample withdrawal
06

Study locations

2 of 2 sites recruiting
  • Hematology Laboratory
    Haifa, Israel
    Recruiting
  • Oncology Institution, Rambam Health Campus
    Haifa, Israel
    Recruiting
07

References and documents

Publications

  • Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001 Feb 1;110(2):91-6. doi: 10.1016/s0002-9343(00)00691-4. PubMed 11165549 ↗
  • Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004 Oct;2(10):1760-5. doi: 10.1111/j.1538-7836.2004.00928.x. PubMed 15456487 ↗
  • Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001 Apr;17(4):667-73. doi: 10.1183/09031936.01.17406670. PubMed 11401062 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00192829
Lead sponsor
Rambam Health Care Campus
First posted
Sep 19, 2005
Start date
Jun 2005
Last update
Apr 11, 2007

Study contacts

Galit Sarig, Ph.D
Contact
g_sarig@rambam.health.gov.il
+972-4-8543503
Nissim Haim, M.D
Contact
Galit Sarig, Ph.D
principal investigator · Rambam Health Care Campus
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

Rambam Health Care Campus

Start the discussion